BIOSPECTATOR: RudaCure, 'Rac1 inhibitor' tratamiento de la enfermedad de ojo seco — "Domestic Phase 1 trial in H2"
El CEO Yongho Kim de RudaCure declaró: "Our tratamiento de la enfermedad de ojo seco candidato, the Rac1 inhibitor 'RCI001 (8-oxo-2'-deoxyguanosine),' showed significant daño corneal recovery and increased secreción lagrimal compared to the control drug from day 5 of administration in mouse model studies, with no efectos secundarios observed even after 5–6 weeks of administration," adding, "Esperamos it to fulfill the unmet medical needs of existing drugs that required long-term administration."
Additionally, RudaCure está preparando a pre-IND meeting with the U.S. Food and Drug Administration (FDA) for Phase 2 ensayo clínicos, targeting IND submission by the end of este año or early el próximo año.
RudaCure was founded in 2018 by Professor Yongho Kim of Gachon University College of Medicine and raised KRW 6 billion through Serie A in May. Además de RCI001, RudaCure actualmente está conducting investigación preclínica on TRPV1 antagonist 'RCI002' as a dolor neuropático tratamiento.
